Citius Oncology (CTOR) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Oncology (CTOR) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 54.6% versus a loss of 62.7%. Citius Oncology is the larger company by market cap ($88.3 million vs $54.5 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | ZYBT |
|---|---|---|
| Share price | $0.835 | $1.15 |
| Market cap | $88.31M | $54.50M |
| 1-day change | -2.45% | -0.87% |
| YTD return | -16.50% | -0.01% |
| 1-year return | -54.62% | -62.67% |
| EPS (TTM) | $-0.48 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $8.01 |
| 52-week low | $0.491 | $0.616 |
| Distance from 52-week high | -62.89% | -85.64% |
| Analyst consensus | none | — |
| Avg. price target upside | +379.04% | — |
| Average volume | 99.72K | 5.10M |
| Shares outstanding | 105.76M | 47.39M |
| Employees | — | 269 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Healthcare · Drug Manufacturers - Specialty & Generic
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Healthcare · Drug Manufacturers - Specialty & Generic · 269 employees
CTOR vs ZYBT FAQ
Which is bigger, Citius Oncology or Zhengye Biotechnology?
Citius Oncology (CTOR) is larger, with a market capitalization of $88.31M compared with $54.50M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, CTOR or ZYBT?
CTOR returned -54.62% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.